Phil Febbo

Dr. Phil Febbo was appointed as Chief Medical Officer at Illumina in March 218. In this role, he is responsible for developing and executing the Company’s medical strategy to drive genomic testing into healthcare practice. Dr. Febbo has a successful track record of translational research, clinical excellence and for embedding molecular insights into clinical care.

Immediately before joining Illumina, Dr. Febbo served as CMO of Genomic Health. Prior to his five years at Genomic Health, Dr. Febbo was a Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology.

Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College and an M.D. from UCSF. He completed his internal medicine residency at the Brigham and Women’s Hospital and his fellowship in oncology at the Dana-Farber Cancer Institute. While an Attending Physician in the Genitourinary Oncology Center at Dana-Farber and Instructor at Harvard Medical School, he spent 5 years as a post-doctoral fellow in Dr. Todd Golub’s laboratory at Dana-Farber and the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 24, Dr. Febbo joined the faculty at Duke University Medical Center’s Institute of Genome Sciences and Policy for 6 years until his return to UCSF. Dr. Febbo served as a primary investigator for the Translational Research Program of The Alliance, an NCI-supported cooperative group focused on incorporating biomarkers into large clinical trials.